Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is .
Abbott Laboratories (NYSE:ABT) Q4 2023 Earnings Call Transcript January 24, 2024 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.19 EPS, expectations were $1.19. ABT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and thank you […]